The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The team first focused on a structural feature of the CRISPR Cas9 protein that is key to its success as a genome-editing tool; this structural feature is responsible for binding to the enzyme’s RNA ...

These systems, which the researchers call TIGR (Tandem Interspaced Guide RNA) systems, use RNA to guide them to specific sites on DNA. TIGR systems can be reprogrammed to target any DNA sequence ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

The revision reflects a cautious stance on the anticipated market uptake of Casgevy, CRISPR's gene editing therapy. According to InvestingPro analysis, the stock is currently fairly valued based ...